Eledon Pharmaceuticals, Inc.ELDN
Metabolic9 cited findings · profile updated 2026-08-25
3.35 USDnot live — refreshed daily
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (ELDN) is focused on metabolic research. The company is developing tegoprubart for kidney transplantation, which is currently in a global Phase 3 trial. This trial aims to enroll 600 patients and has a primary endpoint timepoint of 52 weeks.
In the BESTOW study, tegoprubart demonstrated an eGFR difference of 12 mL/min/1.73 m². The mean eGFR for tegoprubart in BESTOW was 74 mL/min/1.73 m², compared to 61 mL/min/1.73 m² for the tacrolimus comparator. Furthermore, the BESTOW study reported 0 BPAR events for tegoprubart, while the tacrolimus comparator had 7 BPAR events, representing a BPAR events rate of 9.4%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| eGFR difference | 12 mL/min/1.73 m² (BESTOW (tegoprubart)) | Eledon Pharmaceuticals, Inc. — SEC 8-K (2026-08-13), p.1 |
| mean eGFR | 74 mL/min/1.73 m² (BESTOW (tegoprubart)) vs 61 mL/min/1.73 m² (BESTOW (tacrolimus comparator)) | Eledon Pharmaceuticals, Inc. — SEC 8-K (2026-08-13), p.1 |
| BPAR events | 0 (BESTOW (tegoprubart)) vs 7 (BESTOW (tacrolimus comparator)) | Eledon Pharmaceuticals, Inc. — SEC 8-K (2026-08-13), p.1 |
| BPAR events rate | 9.4 % (BESTOW (tacrolimus comparator)) | Eledon Pharmaceuticals, Inc. — SEC 8-K (2026-08-13), p.2 |
Key projects
- tegoprubart (kidney transplantation)
tegoprubart is in a global Phase 3 trial for kidney transplantation with an enrollment of 600 patients and a primary endpoint timepoint of 52 weeks.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Metabolic research library →